After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...

Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

See why Novo Nordisk A/S stock is primed for a rebound despite recent declines. Click for more about NVO growth catalysts in ...

Novo Nordisk A/S downgraded after Q3 earnings and weight loss sector risks. Explore valuation, partnerships, and market ...

Staff at the US Federal Trade Commission said it appears Novo Nordisk A/S’ proposed bid for Metsera Inc. “may violate the ...